Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT05054218
Official study title

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

Study summary

Investigators will evaluate the immunogenicity of a third dose of mRNA-1273 SARS-CoV-2 vaccine among cancer patients receiving the recommended third vaccine dose

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedmRNA-1273

The study team can explain what participation involves.

Who it may be forCovid19 · SARS-CoV2 Infection

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 14, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?H. Lee Moffitt Cancer Center and Research Institute

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Interventions being studied
Biological: mRNA-1273
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • At least 18 years of age
  • Is a cancer patient enrolled in the Cancer Patient Immune Response to COVID-19 Vaccine study (a basic science study) MCC 21138 or who has completed the two mRNA-1273 vaccine series prior to March 31, 2021.
  • Understands, agrees and is able to comply with the study procedures and provides written informed consent.
  • Has no known or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reactions to the vaccine or its excipients.
  • Has not received more or less than 2 doses of mRNA-1273 vaccine
Reasons someone may not be able to joinExclusion criteria

Participants who will not return for the third vaccine dose

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Moffitt Cancer CenterTampa, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 14, 2023. Always confirm current availability with the study team.

View original record ↗